For your adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive1
CONTROL THE gMG SYMPTOM JOURNEY AHEAD1-4
Based on MG-ADL assessment of symptoms in the 26-week trial, which measures how gMG affects daily functions through 8 commonly impacted signs or symptoms.1
See Clinical Data Access and Reimbursement
Proven to deliver lasting gMG symptom control1,2,a
More than 2x greater improvement in Myasthenia Gravis Activities of Daily Living (MG-ADL) total score from baseline at Week 26 vs placebo (-3.1 vs -1.4, respectively [P<0.001])1,2


Many patients continued with concomitant medications for gMG throughout the 26 weeks of the study1,4
ULTOMIRIS® (ravulizumab-cwvz) was studied in a randomized, double-blind, placebo-controlled trial. Patients received either ULTOMIRIS (n=86) or placebo (n=89) for 26 weeks.1
aMean (SD) MG-ADL total score at baseline was 8.9 (2.3) for placebo (n=89) and 9.1 (2.6) for ULTOMIRIS (n=86).5
SD, standard deviation.
Explore Efficacy Data Review Safety Data
Reduction in MG-ADL total score in CHAMPION-MG was observed in the OLE period through Year 34
88%
(141/160) of patients experienced a ≥2-point reduction from baseline in MG-ADL total score (at any point) during the study4
Of those attaining a ≥2-point reduction in MG-ADL total score:
42%
(59/141) of patients experienced MSE (at any point) during the study4,b
MSE = MG-ADL score of 0 or 1
Explore Long-term Data Review Long-term Safety
CHAMPION-MG OLE STUDY LIMITATIONS: MSE was not a prespecified endpoint. Results or clinical outcomes should be interpreted with caution since the study was designed to evaluate safety and lacked a control group.
bNine patients in the placebo group who achieved MSE during the RCP were excluded from the MSE analysis.4 MSE, minimal symptom expression; OLE, open label extension; RCP, randomized controlled period.
Predictable, once-every-8-week maintenance dosing starting 2 weeks after an initial weight-based loading dose1
As few as 6 to 7 maintenance infusions per year after an initial loading dose1
Learn About ULTOMIRIS Dosing See Vaccination Requirements
The first and only long-acting complement C5 inhibitor for anti-AChR Ab+ gMGc with immediate, complete, and sustained complement inhibition1,d
The precise mechanism by which ULTOMIRIS exerts its therapeutic effect in gMG patients is not known but is presumed to involve reduction of terminal complement complex C5b-9 deposition at the neuromuscular junction1
cAnti-acetylcholine receptor antibody-positive gMG.
dComplete inhibition of serum-free C5 (concentration of <0.5 μg/mL) was observed by the end of the first ULTOMIRIS intravenous infusion and sustained throughout the entire 26-week treatment period in all adult gMG patients.1
C5, complement component 5; C5b-9, complement system membrane attack complex.
Understand the Mechanism of Action Learn About the ULTOMIRIS Molecule
Find comprehensive, personalized support for your practice and patients to help get them started
Get Your Patients Started
Start your patients on ULTOMIRIS today
Download Prescriber Start Form
ULTOMIRIS, a complement inhibitor, increases the risk of serious infections caused by Neisseria meningitidis [See Warnings and Precautions (5.1)] Life-threatening and fatal meningococcal infections have occurred in patients treated with complement inhibitors. These infections may become rapidly life-threatening or fatal if not recognized and treated early.
  • Complete or update vaccination for meningococcal bacteria (for serogroups A, C, W, Y, and B) at least 2 weeks prior to the first dose of ULTOMIRIS, unless the risks of delaying ULTOMIRIS therapy outweigh the risk of developing a serious infection. Comply with the most current Advisory Committee on Immunization Practices (ACIP) recommendations for vaccinations against meningococcal bacteria in patients receiving a complement inhibitor. See Warnings and Precautions (5.1) for additional guidance on the management of the risk of serious infections caused by meningococcal bacteria.
  • Patients receiving ULTOMIRIS are at increased risk for invasive disease caused by Neisseria meningitidis, even if they develop antibodies following vaccination. Monitor patients for early signs and symptoms of serious meningococcal infections and evaluate immediately if infection is suspected.

Because of the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ULTOMIRIS and SOLIRIS REMS [See Warnings and Precautions (5.2)].

CONTRAINDICATIONS

  • Initiation in patients with unresolved serious Neisseria meningitidis infection.

WARNINGS AND PRECAUTIONS

Serious Meningococcal Infections


ULTOMIRIS, a complement inhibitor, increases a patient’s susceptibility to serious, life-threatening, or fatal infections caused by meningococcal bacteria (septicemia and/or meningitis) in any serogroup, including non-groupable strains. Life-threatening and fatal meningococcal infections have occurred in both vaccinated and unvaccinated patients treated with complement inhibitors.

Revaccinate patients in accordance with ACIP recommendations considering the duration of ULTOMIRIS therapy. Note that ACIP recommends an administration schedule in patients receiving complement inhibitors that differs from the administration schedule in the vaccine prescribing information. If urgent ULTOMIRIS therapy is indicated in a patient who is not up to date with meningococcal vaccines according to ACIP recommendations, provide antibacterial drug prophylaxis and administer meningococcal vaccines as soon as possible. Various durations and regimens of antibacterial drug prophylaxis have been considered, but the optimal durations and drug regimens for prophylaxis and their efficacy have not been studied in unvaccinated or vaccinated patients receiving complement inhibitors, including ULTOMIRIS. The benefits and risks of treatment with ULTOMIRIS, as well as those associated with antibacterial drug prophylaxis in unvaccinated or vaccinated patients, must be considered against the known risks for serious infections caused by Neisseria meningitidis.

Vaccination does not eliminate the risk of serious meningococcal infections, despite development of antibodies following vaccination.

Closely monitor patients for early signs and symptoms of meningococcal infection and evaluate patients immediately if infection is suspected. Inform patients of these signs and symptoms and instruct patients to seek immediate medical care if they occur. Promptly treat known infections. Meningococcal infection may become rapidly life-threatening or fatal if not recognized and treated early. Consider interruption of ULTOMIRIS in patients who are undergoing treatment for serious meningococcal infection depending on the risks of interrupting treatment in the disease being treated.

ULTOMIRIS and SOLIRIS REMS

Due to the risk of serious meningococcal infections, ULTOMIRIS is available only through a restricted program called ULTOMIRIS and SOLIRIS REMS.

Prescribers must enroll in the REMS, counsel patients about the risk of serious meningococcal infection, provide patients with the REMS educational materials, assess patient vaccination status for meningococcal vaccines (against serogroups A, C, W, Y, and B) and vaccinate if needed according to current ACIP recommendations two weeks prior to the first dose of ULTOMIRIS. Antibacterial drug prophylaxis must be prescribed if treatment must be started urgently, and the patient is not up to date with both meningococcal vaccines according to current ACIP recommendations at least two weeks prior to the first dose of ULTOMIRIS. Patients must receive counseling about the need to receive meningococcal vaccines and to take antibiotics as directed, signs and symptoms of meningococcal infection, and be instructed to carry the Patient Safety Card at all times during and for 8 months following ULTOMIRIS treatment.

Further information is available at www.UltSolREMS.com or 1-888-765-4747.

Other Infections

Serious infections with Neisseria species (other than Neisseria meningitidis), including disseminated gonococcal infections, have been reported.

ULTOMIRIS blocks terminal complement activation; therefore, patients may have increased susceptibility to infections, especially with encapsulated bacteria, such as infections caused by Neisseria meningitidis but also Streptococcus pneumoniae, Haemophilus influenzae, and to a lesser extent, Neisseria gonorrhoeae. Patients receiving ULTOMIRIS are at increased risk for infections due to these organisms, even if they develop antibodies following vaccination.

Thromboembolic Event Management

The effect of withdrawal of anticoagulant therapy during treatment with ULTOMIRIS has not been established. Treatment should not alter anticoagulant management.

Infusion-Related Reactions

Administration of ULTOMIRIS may result in systemic infusion-related reactions, including anaphylaxis and hypersensitivity reactions. In clinical trials, infusion-related reactions occurred in approximately 1 to 7% of patients, including lower back pain, abdominal pain, muscle spasms, drop or elevation in blood pressure, rigors, limb discomfort, drug hypersensitivity (allergic reaction), and dysgeusia (bad taste). These reactions did not require discontinuation of ULTOMIRIS. If signs of cardiovascular instability or respiratory compromise occur, interrupt ULTOMIRIS and institute appropriate supportive measures.


ADVERSE REACTIONS

Most common adverse reactions in adult patients with gMG (incidence ≥10%) were diarrhea and upper respiratory tract infection. Serious adverse reactions were reported in 20 (23%) of patients treated with ULTOMIRIS and in 14 (16%) patients receiving placebo. The most frequent serious adverse reactions were infections reported in at least 8 (9%) patients treated with ULTOMIRIS and in 4 (4%) patients treated with placebo. Of these infections, one fatal case of COVID-19 pneumonia was identified in a patient treated with ULTOMIRIS and one case of infection led to discontinuation of ULTOMIRIS.

DRUG INTERACTIONS

Plasma Exchange, Plasmapheresis, and Intravenous Immunoglobulins

Concomitant use of ULTOMIRIS with plasma exchange (PE), plasmapheresis (PP), or intravenous immunoglobulin (IVIg) treatment can reduce serum ravulizumab concentrations and requires a supplemental dose of ULTOMIRIS.

Neonatal Fc Receptor Blockers

Concomitant use of ULTOMIRIS with neonatal Fc receptor (FcRn) blockers (e.g., efgartigimod) may lower systemic exposures and reduce effectiveness of ULTOMIRIS. Closely monitor for reduced effectiveness of ULTOMIRIS.

USE IN SPECIFIC POPULATIONS

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to ULTOMIRIS during pregnancy. Healthcare providers and patients may call 1-833-793-0563 or go to www.UltomirisPregnancyStudy.com to enroll in or to obtain information about the registry.

To report SUSPECTED ADVERSE REACTIONS, contact Alexion Pharmaceuticals, Inc. at 1-844-259-6783 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

ULTOMIRIS is indicated for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody-positive.

Please see full Prescribing Information for ULTOMIRIS, including Boxed WARNING regarding serious and life-threatening or fatal meningococcal infections.
References:
  1. 1. ULTOMIRIS. Prescribing Information. Alexion Pharmaceuticals, Inc.
  2. 2. Data on file. Alexion Pharmaceuticals, Inc.
  3. 3. Muppidi S, et al. MG Composite and MG-QOL15 Study Group. Muscle Nerve. 2011;44(5):727-731.
  4. 4. Vu TH, et al. Eur J Neurol. 2025;32(4):e70158.
  5. 5. Vu TH, et al. NEJM Evid. 2022;1(5):1-12.
 advance OK Visit Patient Site